GlassScriptPhysician profile
Jose A Velez
NPI 1578744538
$6,168.95
in general payments reported to CMS, 2019-2025
33 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $317 · 2021: $604 · 2022: $1,042 · 2023: $1,301 · 2024: $1,020 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $5.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.70 |
| Education | $5.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $931.15 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $867.81 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $556.61 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Travere Therapeutics, INC. | $449.48 | 2022-2025 | Filspari |
| Janssen Pharmaceuticals, INC | $284.78 | 2019-2022 | |
| Medtronic, INC. | $273.58 | 2023-2024 | Symplicity G3, Onyx Frontier |
| Vifor Pharma, INC. | $265.91 | 2020-2023 | Korsuva, Veltassa |
| Novartis Pharmaceuticals Corporation | $263.26 | 2020-2025 | |
| Akebia Therapeutics INC | $259.41 | 2019-2024 | Auryxia, Vafseo |
| Novo Nordisk INC | $227.88 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Veloxis Pharmaceuticals, INC. | $211.09 | 2019-2025 | Envarsus |
| Horizon Therapeutics Plc | $173.58 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $164.99 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $153.73 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $136.17 | 2020-2025 | Velphoro, Korsuva, Velphoro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $124.91 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $96.20 | 2022-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $93.00 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $88.60 | 2024-2025 | Tarpeyo |
| Lilly USA, LLC | $83.03 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $77.94 | 2024-2025 | Ibsrela |
| Outset Medical INC | $64.41 | 2022 | |
| Daiichi Sankyo INC. | $58.67 | 2019-2022 | |
| Kyowa Kirin, INC. | $55.98 | 2023 | Crysvita |
| Mallinckrodt Enterprises LLC | $40.85 | 2019 | |
| Cormedix INC. | $36.73 | 2024 | Defencath |
| Nxstage Medical, INC. | $26.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2023 | Tradjenta, Jardiance |
| Alexion Pharmaceuticals, INC. | $19.63 | 2024 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.